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Effects of Aldosterone on the Heart
Beyond Systemic Hemodynamics?
Javier Dı´ez
As predicted by Laplace’s law, the ability of the leftventricle to compensate for increasing loading condi-
tions requires the thickening of the ventricular wall and the
growth of left ventricular mass (LVM), defined as left
ventricular hypertrophy (LVH) when it exceeds partition
values based on distribution in normal reference populations.
The presence of LVH, however, does not discriminate be-
tween a compensatory and excessive increase in LVM.
Therefore, the term “inappropriate LVM” (iLVM) has been
applied to conditions in which the observed level of LVM
exceeds the theoretical value predicted by sex, body size, and
stroke work.1 iLVM is associated with clustered geometric
and functional abnormalities of the left ventricle2 and appears
to be a marker of adverse cardiovascular prognosis indepen-
dent of LVH.3 Recent data suggest that changes in the
appropriateness of LVM from baseline to follow-up during
treatment may predict a subsequent cardiovascular event in
hypertensive patients.4 It has been proposed that the patho-
physiological process that yields iLVM is probably linked to
the protracted activity over time of humoral mediators of LV
growth, such as proto-oncogenes, growth factors, hormones,
and cytokines, inducing modifications that initially compen-
sate imposed overload but eventually change the structure of
myocardial tissue (eg, remodeling) and, as a consequence,
impair LV function.5
The study by Muiesan et al in this issue of Hypertension6
points to aldosterone as one of the candidate hormones that
may contribute to iLVM. The authors evaluated the inappro-
priateness of LVM in 125 patients with a diagnosis of
primary aldosteronism (PA) and in 125 age-, sex-, and blood
pressure–matched patients with essential hypertension. The
prevalence of iLVM (defined by a ratio of observed:predicted
LVM 135%) was greater in PA patients than in essential
hypertension patients, irrespective of the presence or absence
of traditionally defined LVH. In addition, direct correlations
were observed between the ratio of observed:predicted LVM
and the ratio of aldosterone:plasma renin activity levels or the
postsaline infusion aldosterone concentration in PA patients.
The study by Muiesan et al6 is timely, because PA is much
more common than previously held, and it implies excessive
organ damage to the heart, vessels, and kidney, which
translates into an excess of cardiovascular events. One of the
main features of the study is the careful biochemical, mor-
phological, and hormonal methodology for the screening and
confirmation of PA, as well as the adequate estimation of the
appropriateness of LVM for individual cardiac load from the
echocardiographic measurements. Thus, the reported findings
provide compelling evidence that the chronic augmentation
of aldosterone could contribute to the increase of LVM
exceeding the amount needed to compensate for hemodynam-
ic load in patients with PA.
Findings from a number of experimental studies suggest
that aldosterone has the potential to directly stimulate LV
growth independent of its effects on renal sodium (Na)
regulation and secondary modulation of blood pressure. For
instance, transgenic mice overexpressing 11-hydroxysteroid
dehydrogenase type 2 in cardiomyocytes, which facilitates
aldosterone occupancy of the mineralocorticoid receptor
(MR), exhibit normal blood pressure values but spontane-
ously develop severe LVH.7 In addition, subcutaneous infu-
sion of nonhypertensive doses of aldosterone to normotensive
rats leads to LVH independent from blood pressure.8 Finally,
also in normotensive rats, a high-salt intake for 8 weeks
produces LVH associated with increased cardiac aldosterone
production and aldosterone-synthase overactivity in the ab-
sence of blood pressure elevation.9
Several studies have investigated the direct hypertrophic
effects of aldosterone on rat cardiac myocytes. In one study,10
aldosterone caused a 27% increase in protein incorporation
and a 29% increase in myocyte surface area. This response
was associated with increased mRNA levels of atrial natri-
uretic factor and - and -myosin heavy chain, and it was
suppressed by the MR antagonist spironolactone. Aldosterone
stimulation acutely translocated protein kinase C- to the
membrane fraction and increased the levels of phosphorylat-
ed extracellular signal-regulated kinases 1/2 and c-Jun
N-terminal kinase. PD 98059, an inhibitor of the extracellular
signal regulated kinase activator mitogen-activated protein
kinase, and bisindolylmaleimide I, an inhibitor of protein
kinase C activation, each blocked aldosterone-stimulated
hypertrophy. In another study,11 aldosterone significantly
increased cell size by 61% and expression of atrial natriuretic
peptide by 2-fold. Na/H exchanger type 1 mRNA expres-
sion and protein abundance were significantly increased, and
intracellular Na levels were elevated. Both hypertrophy and
elevated Na levels were prevented by the NHE-1–specific
inhibitor EMD87580, as well as by spironolactone, although
the increased Na/H exchanger type 1 levels were prevented
only by spironolactone. Finally, it has been reported that
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aldosterone provoked expression of hypertrophic markers
(genes encoding for atrial and brain natriuretic peptides, and
skeletal -actin) and phosphorylation of protein kinase D.12
Inhibition of protein kinase D abrogated the hypertrophic
effects, as did spironolactone. Collectively, these data suggest
that the growth response elicited by aldosterone in myocytes
depends on stimulation of the MR and is associated with
activation of several kinase-mediated pathways and stimula-
tion of Na/H exchanger type 1 expression and activity.
Other than hypertrophy of cardiac myocytes, aldosterone
may also contribute to interstitial and perivascular fibrosis,
another histomorphologic component of myocardial remod-
eling associated with exaggerated LV growth. In fact, chronic
aldosterone infusion causes myocardial fibrosis in rat models
in the setting of high-salt intake.13 The development of
fibrosis is preceded by coronary and myocardial inflamma-
tion characterized by monocyte and macrophage infiltration
and increased production of reactive oxygen species. The
inflammatory and oxidative changes and subsequent fibrosis
can be blocked by MR antagonism. Because animal models
of aldosterone-stimulated cardiac fibrosis involve the sys-
temic administration of aldosterone and salt excess, it has
been difficult to dissect local fibrotic effects of aldosterone
from systemic effects of Na retention. Nevertheless, it is to
be noted that aldosterone has been shown to directly stimulate
the expression of several profibrotic molecules that may
contribute to the pathogenesis of cardiac fibrosis. For exam-
ple, aldosterone increases the activity of transforming growth
factor-1 in cultured cardiac myocytes and its expression in
cultured cardiac fibroblasts, these effects being abrogated by
MR antagonists.14 In addition, aldosterone increases angio-
tensin II type 1 receptor mRNA expression and angiotensin II
type 1 receptor binding in the heart, whereas MR antagonism
decreases angiotensin II type 1 receptor mRNA and density in
the heart and abrogates many of the adverse cardiac effects of
aldosterone, including fibrosis.15
Thus, a relationship is emerging between aldosterone and
the heart, beyond the ability of the hormone to facilitate Na
retention and increase blood pressure, involving the activa-
tion of MR-dependent pathways in cardiac cells by the
hormone (Figure). Continuing research in vitro and in vivo in
animal models is required to discern a number of aspects,
such as the ligand specificity of MR activation, the role for
MR-dependent compared with -independent effects, and the
importance of genomic compared with nongenomic path-
ways, as well as the potential contribution of an intracardiac
synthesis of aldosterone. A general question raised by the
study of Muiesan et al6 is whether the association of aldoste-
rone with iLVM could be also translated to other conditions
in which inappropriately high aldosterone concentrations
coexist with increased blood pressure and exaggerated prev-
alence of LVH (eg, resistant hypertension and sleep apnea) or
with the presence of iLVM (eg, obesity and metabolic
syndrome).16 In this context, clinical trials are needed to
evaluate whether MR antagonists exert a beneficial effect on
LVM in patients with the above conditions and whether this
effect is not only because of their ability to reduce blood
pressure but also because of their ability to block the cardiac
hypertrophic actions of aldosterone.
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Figure. Schematic view of the systemic and cardiac pathways involved in the ability of aldosterone to produce the structural remodel-
ing of the myocardium responsible for the inappropriate growth of LVM present in conditions associated with an excessive synthesis
and secretion of the hormone by the adrenal gland. BP indicates blood pressure.
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